OncLive TV

Raji Shameem, MD, discusses first-line treatment planning for pancreatic adenocarcinoma including clinical trial eligibility alongside standard chemotherapy options.

Kristen Spencer, DO, discusses first-line regimen selection in metastatic pancreatic adenocarcinoma.

Yue Wei, PhD, discusses how HMAs promote late-stage megakaryocyte maturation and platelet production in MDS mouse models.

Robert Neff, MD, discusses the potential benefits of self-collected HPV testing and the challenges of implementing this screening method in practice.

Marc J. Braunstein, MD, PhD, discusses the clinical implications of the FDA approval of subcutaneous daratumumab with VRd for newly diagnosed multiple myeloma, ineligible ASCT.

Guillermo Garcia-Manero, MD, discusses the rationale and design of the GLORA-4 trial evaluating lisaftoclax plus azacitidine in high-risk MDS.

Aditya Bardia, MD, MPH, FASCO, discussed data from the lidERA trial of giredestrant vs SOC endocrine therapy in ER-positive, HER2-negative breast cancer.

Natalie Callander, MD, discusses the role of ALC monitoring in the management of relapsed/refractory multiple myeloma following CAR T-cell therapy.

Enriqueta Felip, MD, PhD, discusses key efficacy data from the MARIPOSA trial and its implications.

William A. Hall, MD, discusses the need for more precise radiation therapy in rectal cancer.

Enriqueta Felip, MD, PhD, discusses EGFR-mutated non-small cell lung cancer and how to approach it from multiple angles.

Kevin Kalinsky, MD, MS, FASCO, discusses safety and quality of life data from ASCENT-04 in PD-L1–positive metastatic TNBC.

Komal Jhaveri, MD, FACP, discusses lessons learned from the negative phase 3 ASCENT-07 trial in hormone receptor–positive, HER2-negative breast cancer.

Shaji Kumar, MD, shares phase 1 data from the CAMMA 1 trial evaluating cevostamab alone or in different combinations in relapsed/refractory myeloma.

Maxwell Lloyd, MD, discusses phase 3 data from DESTINY-Breast11 and DESTINY-Breast05 evaluating T-DXd in neoadjuvant and adjuvant HER2-positive breast cancer.

Yue Wei, PhD, discusses the correlation between TET2 mutations and platelet recovery in patients with MDS receiving hypomethylating agents.

Kanwal P.S. Raghav, MBBS, MD, discusses the mechanism of action of telisotuzumab adizutecan in post-adjuvant ctDNA-positive CRC.

Peter Voorhees, MD, discussed significance of the FDA approval of daratumumab and hyaluronidase for adult patients with high-risk smoldering multiple myeloma.

Xiuning Le, MD, PhD, discusses the significance of the FDA’s approval of sevabertinib for locally advanced/metastatic, nonsquamous HER2-positive NSCLC.

Rocío García-Carbonero, MD, discusses the rationale of the FRESCO-2 trial of fruquintinib in mCRC.

Eric K. Singhi, MD, discuses the emerging role of TROP2-directed antibody–drug conjugates in the evolving treatment algorithm for NSCLC.

Laura Alder, MD, discusses clinical decision-making around prioritizing local vs systemic therapy for patients with lung cancer who present with CNS-only metastatic disease.

William A. Hall, MD, discusses remaining clinical questions in the field of rectal cancer.

Christof Vulsteke, MD, PhD, discusses the clinical rationale for evaluating perioperative enfortumab vedotinplus pembrolizumab in patients with cisplatin-ineligible MIBC.

Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for examining telisotuzumab adizutecan in post-adjuvant ctDNA-positive CRC.

Yue Wei, PhD, discusses how TET2 mutations influence platelet response and prognosis in patients with MDS receiving hypomethylating agents.

Hans Lee, MD, discusses the role of the CoMMit consortium as a collaborative forum shaping the future of multiple myeloma research.

Jason Aboudi Mouabbi, MD, discussed the importance of using ctDNA testing to inform treatment decision-making across breast cancer populations.

Hope S. Rugo, MD, highlights emerging research with targeted therapies and oral SERDs that may influence the HR-positive breast cancer treatment paradigm.